Adagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-14 · Company identity, CIK, ticker, exchange, SIC, and filing sequence.SEC APISEC companyfacts JSON2026-05-14 · XBRL cross-check for revenue, net loss, R&D, cash, assets, liabilities, operating cash flow, and shares.SEC filingFY2025 Form 20-F2026-04-01 · Business model, platform description, FY2025 audited financials, ADS ratio, holding-company structure, no-VIE disclosure, and risk factors.Company release furnished to SECFY2025 financial results and corporate update2026-04-01 · Cash runway, 2026 objectives, collaboration summary, clinical update, and financial highlights.Company release furnished to SECIncyte collaboration release2026-04-02 · Muzastotug plus INCA33890 study design, Incyte sponsorship, and Adagene supply role.Company release furnished to SECUpdated muzastotug clinical data release2026-04-02 · 20 mg/kg versus 10 mg/kg ORR, PFS, safety, Fast Track, and Phase 2 timing claims.SEC offering filingApril 2026 prospectus supplement2026-04-02 · ADS offering size, price, estimated net proceeds, use of proceeds, dilution, and pipeline disclosure.Company release furnished to SECAACR 2026 update2026-04-17 · HCC and MSS CRC triplet-combination interim data and tolerability claims.Company release furnished to SECThird Arc licensing release2025-11-13 · SAFEbody license terms for masked CD3 T-cell engagers.SEC filingSanofi strategic investment 6-K2025-07-01 · Sanofi investment size, first and second closing mechanics, and intended use for muzastotug Phase 2.